SEC Form SC 13G/A filed by The Oncology Institute Inc. (Amendment)
$TOI
Medical/Nursing Services
Health Care
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/25/2025 | $5.00 | Buy | Needham |
| 7/23/2025 | $8.00 | Outperform | Noble Capital Markets |
| 7/16/2025 | $6.00 | Buy | B. Riley Securities |
| 5/15/2025 | $7.00 | Buy | BTIG Research |
| 2/26/2024 | $2.50 | Buy | Jefferies |
| 9/14/2022 | $7.00 | Buy | Guggenheim |
| 8/15/2022 | $10.00 | Buy | Jefferies |
CERRITOS, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. ("TOI") (NASDAQ:TOI), one of the largest value-based oncology groups in the United States, today announced that Yale D. Podnos, MD, MPH, FACS, Chief Medical Officer, will participate in a panel discussion at the APG Spring Conference on May 28, 2026, in San Diego. The session, "Engaging More Specialists in Value-Based Care," will bring together healthcare leaders to discuss the growing role of specialists in advancing value-based care. "Specialists play a critical role in delivering high-quality, coordinated care while helping improve outcomes and reduce the total cost of care," said Dr. Podnos. "As oncology c
CERRITOS, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ:TOI), one of the largest value-based oncology groups in the United States, today announced that Dr. Daniel Virnich, Chief Executive Officer, and Rob Carter, Chief Financial Officer, will participate in the B. Riley Securities Institutional Investor Conference, being held in Marina Del Rey, CA on Thursday, May 21, 2026, including a fireside chat from 9:00–9:40 a.m. PT. A webcast link of the presentation will be accessible through the Investor Relations section of the Company's website at https://investors.theoncologyinstitute.com/. ____________________________ About The Oncology Institute (www.theonco
CERRITOS, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ:TOI) ("TOI" or the "Company"), one of the largest value-based community oncology groups in the United States, today reported financial results for its three months ended March 31, 2026. Recent Operational Highlights Specialty Pharmacy had record Part D fills driving Specialty Pharmacy revenue up 78% in the quarter as compared to prior year same quarter, reflecting the volume growth across our membership and continued attachment rate improvements.Contract expansion bringing our total Medicare Advantage lives to 200,000 across 25 counties in Florida effective July 1, 2026. Preparing to launch our propr
8-K - Oncology Institute, Inc. (0001799191) (Filer)
SCHEDULE 13D/A - Oncology Institute, Inc. (0001799191) (Subject)
8-K - Oncology Institute, Inc. (0001799191) (Filer)
4 - Oncology Institute, Inc. (0001799191) (Issuer)
4 - Oncology Institute, Inc. (0001799191) (Issuer)
4 - Oncology Institute, Inc. (0001799191) (Issuer)
Needham initiated coverage of The Oncology Institute with a rating of Buy and set a new price target of $5.00
Noble Capital Markets initiated coverage of The Oncology Institute with a rating of Outperform and set a new price target of $8.00
B. Riley Securities initiated coverage of The Oncology Institute with a rating of Buy and set a new price target of $6.00
4 - Oncology Institute, Inc. (0001799191) (Issuer)
4 - Oncology Institute, Inc. (0001799191) (Issuer)
4 - Oncology Institute, Inc. (0001799191) (Issuer)
SC 13D/A - Oncology Institute, Inc. (0001799191) (Subject)
SC 13D/A - Oncology Institute, Inc. (0001799191) (Subject)
SC 13G/A - Oncology Institute, Inc. (0001799191) (Subject)
CERRITOS, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ:TOI) ("TOI" or the "Company"), one of the largest value-based community oncology groups in the United States, today reported financial results for its three months ended March 31, 2026. Recent Operational Highlights Specialty Pharmacy had record Part D fills driving Specialty Pharmacy revenue up 78% in the quarter as compared to prior year same quarter, reflecting the volume growth across our membership and continued attachment rate improvements.Contract expansion bringing our total Medicare Advantage lives to 200,000 across 25 counties in Florida effective July 1, 2026. Preparing to launch our propr
CERRITOS, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. ("TOI") (NASDAQ:TOI) a pioneer in value-based community oncology care, today announced that the company will release its first quarter 2026 financial results on Thursday, May 7, 2026, to be followed by a conference call the same day at 5:30 p.m. (Eastern Time). The conference call can be accessed live over the phone by dialing 1-800-225-9448 or for international callers, 1-203-518-9708. A replay will be available two hours after the call and can be accessed by dialing 1-844-512-2921, or for international callers, 1-412-317-6671. The passcode for the live call and the replay is 11161701. The replay will be av
CERRITOS, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ:TOI) ("TOI" or the "Company"), one of the largest value-based community oncology groups in the United States, today reported financial results for its fourth quarter and year ended December 31, 2025. Recent Operational Highlights Cash flow from operations in Q4 2025 was approximately $3.2 million, due to disciplined working capital management and overall increase in gross profit marginContinued expansion of our capitated footprint, initiating 9 new capitated contracts during 2025 in CA, FL, and NV, representing approximately 260,000 additional lives under managementFurther ramped our capitation
CERRITOS, Calif., April 06, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. ("TOI") (NASDAQ:TOI), one of the largest value-based oncology groups in the United States, today announced that Minh Merchant has joined the organization as Chief Legal Officer. In this role, Ms. Merchant will oversee legal, regulatory, compliance and privacy functions as TOI continues to scale. This role will be essential in enabling the company to continue its growth trajectory while further enhancing its mission to be a trusted healthcare partner to oncology patients and payors. Ms. Merchant has more than two decades of experience advising public and private healthcare organizations, including significant
CERRITOS, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. ("TOI") (NASDAQ:TOI), one of the largest value-based oncology groups in the United States, today announced the appointment of Kim Tzoumakas to its Board of Directors, effective February 23, 2026. Ms. Tzoumakas brings more than two decades of executive leadership experience across oncology, pharmacy services and healthcare operations. Notably, she is Chief Executive Officer for VytlOne National Pharmacy Services, and previously held the CEO role at 21st Century Oncology, where she successfully led the organization through a multi-year operational turnaround, culminating in its strategic sale. She also has serve
CERRITOS, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. ("TOI") (NASDAQ:TOI), one of the largest value-based oncology groups in the United States, today announced that Mark Stolper has joined the Board of Directors, effective January 2, 2026. Mr. Stolper brings significant public markets, financial and operational leadership experience to The Oncology Institute's board. Mr. Stolper serves as Executive Vice President and Chief Financial Officer of RadNet, Inc. (NASDAQ:RDNT), a position he has held since 2004. Mr. Stolper has also been a member of the Board of Directors of various publicly traded and privately held healthcare companies, including 21st Century Oncolog